A Lactation Study in Women Who Are Breastfeeding or Pumping and Are Receiving Linaclotide Therapeutically
Forest Laboratories · Breast Feeding · Constipation
Phase 1
Completed
7
2020-12
Industry sponsor intelligence
Forest LaboratoriesClinical Pipeline.
Lead-sponsor view of Forest Laboratories's indexed peptide studies, development phases, active programs, completed work and recent registry changes.
- Total
- 9
- Recruiting
- 0
- Active
- 0
- Completed
- 8
- Results posted
- 8
- Avg enrollment
- 538
Pipeline overview
Programs by phase and activity.
Velocity
Forest Laboratories trials by start year
Study start year · indexed snapshot
Development
Trials by phase
9phase labels
Early Phase 10
Phase 11
Phase 23
Phase 34
Phase 41
| Product | Studies | Early / I | Phase II | Phase III | Phase IV | Active |
|---|---|---|---|---|---|---|
| Linaclotide → | 9 | 1 | 3 | 4 | 1 | 0 |
Active peptide trials
In motion now.
No studies in this snapshot.
Completed trials
Finished registry records.
NCT IDStudyPhase / statusEnrollmentUpdated
An Open-Label, Long-term Study to Assess the Immunogenicity of LINZESS® (Linaclotide) Administered Orally to Adult Participants With Irritable Bowel Syndrome With Constipation or Chronic Idiopathic Constipation
Forest Laboratories · Irritable Bowel Syndrome With Constipation · Chronic Idiopathic Constipation
Phase 4
Completed
828
2019-08
A Safety and Efficacy Study of a Range of Linaclotide Doses Administered Orally to Children Ages 6-17 Years Who Fulfill Modified Rome III Criteria for Child/Adolescent Functional Constipation (FC)
Forest Laboratories · Functional Constipation in Children Ages 6-17 Years
Phase 2
Completed
173
2019-06
Phase 2 Randomized, Double-Blind, Placebo-Controlled, Parallel Group Trial of Linaclotide Administered to Patients With Opioid-Induced Constipation Receiving Chronic Opioid Treatment for Non-Cancer Pain
Forest Laboratories · Opioid-Induced Constipation
Phase 2
Completed
254
2019-04
An Open-Label, Long-Term Safety Study of Linaclotide in Patients With Chronic Constipation or Irritable Bowel Syndrome With Constipation
Forest Laboratories · Chronic Constipation · Irritable Bowel Syndrome With Constipation
Phase 3
Completed
1,559
2019-02
Safety and Efficacy of Linaclotide in Patients With Chronic Constipation and Prominent Abdominal Bloating
Forest Laboratories · Chronic Constipation · Constipation
Phase 3
Completed
487
2016-04
Phase III, Randomized, Double-Blind, Placebo-Controlled, Trial of Linaclotide Administered to Patients With Chronic Constipation
Forest Laboratories · Chronic Constipation
Phase 3
Completed
633
2013-01
Trial of Linaclotide Administered to Patients With Irritable Bowel Syndrome With Constipation
Forest Laboratories · Irritable Bowel Syndrome Characterized by Constipation
Phase 3
Completed
803
2013-01
Search sponsor records
All Forest Laboratories studies.
This page groups studies where Forest Laboratories is listed as the lead industry sponsor. Collaborator-only records are not included in the count.
9 matching studies
Last registry update first
Recent updates
Latest registry movement.
NCT02559817A Safety and Efficacy Study of a Range of Linaclotide Doses Administered Orally to Children Ages 7-17 Years, With Irritable Bowel Syndrome With ConstipationDec 28, 2020NCT02220348A Lactation Study in Women Who Are Breastfeeding or Pumping and Are Receiving Linaclotide TherapeuticallyDec 19, 2020NCT02590432An Open-Label, Long-term Study to Assess the Immunogenicity of LINZESS® (Linaclotide) Administered Orally to Adult Participants With Irritable Bowel Syndrome With Constipation or Chronic Idiopathic ConstipationAug 22, 2019NCT02559570A Safety and Efficacy Study of a Range of Linaclotide Doses Administered Orally to Children Ages 6-17 Years Who Fulfill Modified Rome III Criteria for Child/Adolescent Functional Constipation (FC)Jun 19, 2019NCT02270983Phase 2 Randomized, Double-Blind, Placebo-Controlled, Parallel Group Trial of Linaclotide Administered to Patients With Opioid-Induced Constipation Receiving Chronic Opioid Treatment for Non-Cancer PainApr 8, 2019NCT00765999An Open-Label, Long-Term Safety Study of Linaclotide in Patients With Chronic Constipation or Irritable Bowel Syndrome With ConstipationFeb 15, 2019NCT01642914Safety and Efficacy of Linaclotide in Patients With Chronic Constipation and Prominent Abdominal BloatingApr 26, 2016NCT00765882Phase III, Randomized, Double-Blind, Placebo-Controlled, Trial of Linaclotide Administered to Patients With Chronic ConstipationJan 30, 2013NCT00948818Trial of Linaclotide Administered to Patients With Irritable Bowel Syndrome With ConstipationJan 30, 2013